In this respect, we have previously performed an in vivo study using three human colorectal cancer cell lines highly sensitive to EGFR inhibitors, in order to evaluate which maintenance treatment with different inhibitors that act downstream to the EGFR pathway would be able to prevent and/or delay the onset of resistance after an induction treatment with cetuximab plus irinotecan [16]. Here, EGFR is linked to colorectal cancer.